Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) surged 24.9% last week after receiving $100 million from Sarepta Therapeutics Inc. (NASDAQ:SRPT) as part of a licensing agreement. $50 million was paid in shares, boosting value for investors. Arrowhead plans to use the remaining $50 million to reduce outstanding shares. President Christopher Anzalone expressed confidence in the collaboration.

The $100 million payment was based on Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) reaching the first enrollment target for an early-stage clinical trial of ARO-DM1, a therapy for type 1 myotonic dystrophy (DM1). Further milestones will be paid in cash. While ARWR shows potential for investment, other AI stocks may offer greater returns with less risk. For a cheap AI stock benefiting from Trump tariffs, check out our free report.

Read more at Yahoo Finance: Arrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue